United-Guardian, Inc. — Q2 2020 Form 10-Q
Business context and period. The company develops, manufactures and markets cosmetic ingredients, pharmaceutical and medical products, and specialty industrial products. This unaudited filing covers the three and six months ended June 30, 2020, compared with the corresponding 2019 periods.
Financial performance
| Metric | Q2 2020 | Q2 2019 | First half 2020 | First half 2019 |
|---|---|---|---|---|
| Net sales | $2.955 million | $3.279 million | $6.278 million | $6.460 million |
| Income from operations | $1.064 million | $1.216 million | $2.375 million | $2.462 million |
| Net income | $1.187 million | $1.079 million | $1.977 million | $2.302 million |
| Diluted EPS | $0.26 | $0.23 | $0.43 | $0.50 |
- Q2 sales fell 10%; first-half sales fell 3%. Q2 operating income declined 13%, while first-half operating income declined 4%.
- Q2 net income rose 10%, despite lower operating income, largely reflecting a $387,179 gain on marketable securities versus $86,849 a year earlier. First-half net income fell 14%, with securities gains of $30,584 versus $344,043 in 2019.
- Gross margin was approximately 57% in Q2 2020 versus 55% in Q2 2019, and approximately 58% versus 57% for the first half. The company attributed the improvement to lower production and overhead costs.
- First-half operating cash flow was $3.183 million, compared with $2.643 million. Cash increased to $2.207 million from $1.048 million at year-end 2019.
- At June 30, cash and marketable securities totaled $9.198 million; current assets were $12.113 million and current liabilities $2.025 million. Working capital was $10.088 million and the current ratio was 6.0:1, down from $10.224 million and 8.6:1 at year-end. The balance sheet reports no debt.
- First-half investing cash outflow was $95,802; financing cash outflow was $1.929 million, primarily dividends. The dividend was $0.42 per share, down from $0.55 per share in 2019.
Material changes and management commentary
- Cosmetic ingredients: Sales fell 23% in Q2 and 9% in the first half, mainly because of lower demand in China through marketing partner Ashland Specialty Ingredients (ASI), as well as lower-priced competition, particularly in Asia.
- Pharmaceuticals: Sales increased 20% in Q2 and 19% in the first half, primarily from higher Renacidin sales. Management linked the increase to marketing efforts, including a new website and internet advertising. Clorpactin sales declined.
- Medical products: Sales declined 22% in Q2 and 18% in the first half, mainly due to lower orders from three customers. Management believes the pandemic contributed to the decline.
- COVID-19-related reductions in cosmetic and medical product demand were expected to continue, potentially beyond 2020. The company said it could not reliably estimate the pandemic’s full impact. Pharmaceutical sales had not been affected year to date, and management did not then expect them to be affected.
- The company remained open as an essential business. Staggered hours slightly affected Q2 production, but management reported sufficient inventory and timely order fulfillment; it expected raw-material supply and production capacity to remain adequate.
- Management stated working capital should support operations for at least 12 months, expected no significant capital expenditures for the rest of 2020, and said operating expenses should remain relatively consistent. The company provided no specific sales or earnings guidance.
Risks, contingencies and other notable items
- Customer and channel concentration is material: one marketing partner and three distributors represented 76% of Q2 sales and 64% of receivables at June 30; for the first half, they represented 79% of sales and 64% of receivables.
- ASI-reported sales of the company’s products were geographically exposed: China accounted for approximately 42% of ASI’s Q2 sales of those products, versus 54% in Q2 2019. ASI shipments are reported as U.S. sales in the company’s geographic data.
- Marketable securities are exposed to market-value fluctuations. Q2 securities gains included a substantial recovery from first-quarter unrealized losses; the filing reports $25,728 of first-half unrealized gains on securities still held.
- COVID-19 could continue to reduce demand and delay customer payments, although management did not expect a material increase in bad debts or impairment of liquidity. No legal proceedings or off-balance-sheet arrangements were reported.
Important facts for investors to verify
- Whether demand in China and other markets, particularly for cosmetic ingredients, recovers and how lower-priced competition affects pricing and margins.
- Whether delayed medical-product orders resume, and whether pharmaceutical growth—especially Renacidin—continues.
- The durability and composition of investment gains, and the market risk in the company’s securities portfolio.
- How concentrated sales and receivables remain among the principal marketing partner and distributors.
- Future dividend levels and cash deployment; the filing gives no specific earnings or revenue forecast.